895P - The role of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT in the prognosis of epithelial ovarian cancer

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Ovarian Cancer
Staging Procedures (clinical staging)
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Jeong Won Lee
Citation Annals of Oncology (2014) 25 (suppl_4): iv305-iv326. 10.1093/annonc/mdu338
Authors J.W. Lee1, S.M. Lee2, W.J. Kang1, J.D. Lee1, Y.T. Kim3
  • 1Department Of Nuclear Medicine, Yonsei University College of Medicine, 120-752 - Seoul/KR
  • 2Department Of Nuclear Medicine, Soonchunhyang University Hospital, 330-721 - Cheonan/KR
  • 3Department Of Obstetrics And Gynecology, Yonsei University College of Medicine, 120-752 - Seoul/KR



This study assessed the prognostic value of pre-operative 2-[18F] fluoro-2-deoxy-d-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) volumetric parameters, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), in patients with epithelial ovarian cancer.


A total of 166 patients with epithelial ovarian cancer who underwent 18F-FDG PET/CT and subsequent cytoreductive surgery were retrospectively enrolled. Maximum standardized uptake value (SUVmax), MTV, and TLG on 18F-FDG PET/CT were measured for all patients. Univariate and multivariate analyses were performed to evaluate the prognostic significance of SUVmax, MTV, TLG, and clinicopathological factors for disease progression-free survival.


Disease progressed in 78 (47%) of the 166 patients, and the 2-year disease progression-free survival rate was 55.0%. Univariate analysis showed that tumor stage, histopathological type, presence of regional lymph node metastasis, residual tumor after cytoreductive surgery, pre-operative serum carbohydrate antigen 125 (CA125) level, SUVmax, MTV, and TLG were significant prognostic factors (p < 0.05). Among these variables, tumor stage (p = 0.0006) and TLG (p = 0.008) independently correlated with disease progression-free survival on multivariate analysis. The disease progression rate was only 2.3% in stage I-II patients with low TLG (≤100.0), compared to 80.0% in stage III-IV patients with high TLG (>100.0).


Along with tumor stage, TLG is an independent prognostic factor for disease progression after cytoreductive surgery in patients with epithelial ovarian cancer. By combining tumor stage and TLG, one can further stratify the risk of disease progression for patients undergoing cytoreductive surgery.


All authors have declared no conflicts of interest.